JP2007506699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506699A5 JP2007506699A5 JP2006527365A JP2006527365A JP2007506699A5 JP 2007506699 A5 JP2007506699 A5 JP 2007506699A5 JP 2006527365 A JP2006527365 A JP 2006527365A JP 2006527365 A JP2006527365 A JP 2006527365A JP 2007506699 A5 JP2007506699 A5 JP 2007506699A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- bishomo
- epi
- diene
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- LRLWXBHFPGSUOX-GJQYOBCGSA-N (1r,3z,5s)-3-[(2e)-2-[(3as,7as)-1-[(e,2s)-6-ethyl-6-hydroxyoct-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-ylidene]ethylidene]-5-fluoro-4-methylidenecyclohexan-1-ol Chemical compound C1(/[C@@H]2CC=C([C@]2(CCC1)C)[C@@H](C)C/C=C/C(O)(CC)CC)=C\C=C1\C[C@@H](O)C[C@H](F)C1=C LRLWXBHFPGSUOX-GJQYOBCGSA-N 0.000 claims 8
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 7
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 4
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 2
- 235000019864 coconut oil Nutrition 0.000 claims 2
- 239000003240 coconut oil Substances 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 239000003087 receptor blocking agent Substances 0.000 claims 2
- 206010069632 Bladder dysfunction Diseases 0.000 claims 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims 1
- 229960001389 doxazosin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960004199 dutasteride Drugs 0.000 claims 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960004039 finasteride Drugs 0.000 claims 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 229960004953 silodosin Drugs 0.000 claims 1
- PNCPYILNMDWPEY-QGZVFWFLSA-N silodosin Chemical compound N([C@@H](CC=1C=C(C=2N(CCCO)CCC=2C=1)C(N)=O)C)CCOC1=CC=CC=C1OCC(F)(F)F PNCPYILNMDWPEY-QGZVFWFLSA-N 0.000 claims 1
- 229960002613 tamsulosin Drugs 0.000 claims 1
- 229960001693 terazosin Drugs 0.000 claims 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical group N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0322395A GB0322395D0 (en) | 2003-09-24 | 2003-09-24 | Methods for treating bladder dysfunction and related compounds and compositions |
| GB0325598A GB2407499B (en) | 2003-11-03 | 2003-11-03 | Vitamin D3 analogue for use in the treatment of BPH |
| GB0416876A GB0416876D0 (en) | 2004-07-29 | 2004-07-29 | Compound and use in treatment |
| PCT/EP2004/010760 WO2005027923A1 (en) | 2003-09-24 | 2004-09-24 | Use of vitamin d3 analogue for the treatment of benign prostatic hyperplasia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008209429A Division JP2009035559A (ja) | 2003-09-24 | 2008-08-18 | 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007506699A JP2007506699A (ja) | 2007-03-22 |
| JP2007506699A5 true JP2007506699A5 (https=) | 2007-10-25 |
Family
ID=34229055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527365A Abandoned JP2007506699A (ja) | 2003-09-24 | 2004-09-24 | 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用 |
| JP2008209429A Abandoned JP2009035559A (ja) | 2003-09-24 | 2008-08-18 | 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008209429A Abandoned JP2009035559A (ja) | 2003-09-24 | 2008-08-18 | 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1673096A1 (https=) |
| JP (2) | JP2007506699A (https=) |
| CN (1) | CN100488511C (https=) |
| BE (1) | BE1016292A3 (https=) |
| BR (1) | BRPI0404050A (https=) |
| CH (1) | CH698144B1 (https=) |
| EA (1) | EA010240B1 (https=) |
| FR (1) | FR2859910B1 (https=) |
| NL (1) | NL1027109C2 (https=) |
| NZ (1) | NZ535531A (https=) |
| WO (1) | WO2005027923A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090227651A1 (en) * | 2004-10-05 | 2009-09-10 | Kissei Pharmaceutical Co., Ltd. | Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction |
| PL1806136T3 (pl) * | 2004-10-06 | 2012-04-30 | Kissei Pharmaceutical | Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego |
| US20100009949A1 (en) * | 2006-03-24 | 2010-01-14 | Bioxell S.P.A. | Novel method |
| US8221803B1 (en) | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
| US20120164240A1 (en) | 2010-12-22 | 2012-06-28 | Audino David Lawrence | Enriched a. blitoides compositions and uses thereof |
| US20170049834A1 (en) * | 2015-08-18 | 2017-02-23 | Golden Biotechnology Corporation | Benign prostatic hyperplasia add-on therapy |
| FR3063906B1 (fr) * | 2017-03-20 | 2025-12-12 | Pf Medicament | Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate |
| CN120960385A (zh) * | 2025-08-01 | 2025-11-18 | 上海交通大学医学院附属第九人民医院 | 5α–还原酶降解分子及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763429A (en) * | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
| TW403735B (en) * | 1995-11-22 | 2000-09-01 | Hoffmann La Roche | 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol |
| SG70009A1 (en) * | 1996-05-23 | 2000-01-25 | Hoffmann La Roche | Vitamin d3 analogs |
| CA2289209C (en) * | 1997-05-16 | 2006-07-25 | Women & Infants Hospital | Cyclic ether vitamin d3 compounds, 1.alpha. (oh) 3-epi-vitamin d3 compounds and uses thereof |
| US5872113A (en) * | 1997-05-16 | 1999-02-16 | Syntex (U.S.A.) Inc. | Fluorinated vitamin D3 analogs |
| US6255501B1 (en) * | 1999-04-26 | 2001-07-03 | Hoffman-La Roche Inc. | Process for preparing antiosteoporotic agents |
| WO2003034961A1 (en) * | 2001-10-23 | 2003-05-01 | Euro-Celtique, S.A. | Terazosin transdermal device and methods |
| BR0214679A (pt) * | 2001-12-03 | 2004-12-14 | Novacea Inc | Composições farmacêuticas compreendendo compostos a base de vitamina d ativa |
-
2004
- 2004-09-22 CH CH01553/04A patent/CH698144B1/fr not_active IP Right Cessation
- 2004-09-22 BR BR0404050-3A patent/BRPI0404050A/pt not_active IP Right Cessation
- 2004-09-23 EA EA200401100A patent/EA010240B1/ru not_active IP Right Cessation
- 2004-09-23 NZ NZ535531A patent/NZ535531A/xx unknown
- 2004-09-23 FR FR0410073A patent/FR2859910B1/fr not_active Expired - Fee Related
- 2004-09-24 WO PCT/EP2004/010760 patent/WO2005027923A1/en not_active Ceased
- 2004-09-24 NL NL1027109A patent/NL1027109C2/nl not_active IP Right Cessation
- 2004-09-24 JP JP2006527365A patent/JP2007506699A/ja not_active Abandoned
- 2004-09-24 EP EP04765598A patent/EP1673096A1/en not_active Withdrawn
- 2004-09-24 CN CNB2004100800817A patent/CN100488511C/zh not_active Expired - Fee Related
- 2004-09-24 BE BE2004/0472A patent/BE1016292A3/nl not_active IP Right Cessation
-
2008
- 2008-08-18 JP JP2008209429A patent/JP2009035559A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hamed et al. | Targeting multidrug resistance in cancer by natural chemosensitizers | |
| US20190216779A1 (en) | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions | |
| CA2992404C (en) | Pharmaceutical composition containing celecoxib and tramadol | |
| CA2804341A1 (en) | Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration | |
| EA200601724A1 (ru) | Новые композиции для местной доставки | |
| ES2634020T3 (es) | Formulaciones de compuestos orgánicos | |
| WO2007120485A2 (en) | Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor | |
| JP2007506699A5 (https=) | ||
| AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
| JP2019508464A (ja) | クロピドグレル及びアスピリンを含む複合製剤 | |
| CA2927720A1 (en) | Composite formulation comprising tadalafil and amlodipine | |
| KR20160021095A (ko) | 탐술로신 또는 이의 염의 약학 조성물 | |
| JP6116674B2 (ja) | （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ−［３，４，ｂ］インドール］−４−アミンおよびプロピオン酸誘導体を含む医薬組成物 | |
| RU2010110658A (ru) | Композиции для лечения неопластических заболеваний | |
| PL190733B1 (pl) | Zastosowanie przeciwmigrenowej kombinacji i kompozycja farmaceutyczna do leczenia migreny | |
| HRP20130237T1 (hr) | Formulacije inekalcitola | |
| JP6116677B2 (ja) | （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびオキシカムを含む医薬組成物 | |
| JP6116678B2 (ja) | （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびＮＳＡＲを含む医薬組成物 | |
| Kiss et al. | Renin-Angiotensin-Aldosterone Signaling Inhibitors-Losartan, Enalapril, and Cardosten-Prevent Infarction-induced Heart Failure Development in Rats. | |
| WO2010019279A8 (en) | Pharmaceutical compositions configured to deter dosage form splitting | |
| JP6116676B2 (ja) | （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびパラセタモールまたはプロパセタモールを含む医薬組成物 | |
| JP2020511488A5 (https=) | ||
| TW201216965A (en) | improving the characteristics of Nalbuphine in low oral bioavailability, and developing thenew oral dosage form and new dosage | |
| CN101229163A (zh) | 一种含有左旋氨氯地平与匹伐他汀的药用组合物 | |
| WO2011133010A3 (es) | Composición de yodo molecular de uso humano para la prevención tratamiento de patologías prostáticas |